# Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections

> **NCT02753946** · PHASE2,PHASE3 · COMPLETED · sponsor: **Nabriva Therapeutics AG** · enrollment: 465 (actual)

## Conditions studied

- Urinary Tract Infection Symptomatic
- Acute Pyelonephritis
- Urinary Tract Infection Complicated

## Interventions

- **DRUG:** ZTI-01
- **DRUG:** Piperacillin-tazobactam

## Key facts

- **NCT ID:** NCT02753946
- **Lead sponsor:** Nabriva Therapeutics AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-01-12
- **Final completion:** 2017-05-30
- **Target enrollment:** 465 (ACTUAL)
- **Last updated:** 2019-03-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02753946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02753946, "Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02753946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*